FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029388289> ?p ?o ?g. }

• W2029388289 endingPage "755" @default.
• W2029388289 startingPage "749" @default.
• W2029388289 abstract "BackgroundActivation of the IgE receptor, FcɛRI, in mast cells is the key mechanism initiating and propagating pathophysiological responses in allergic rhinitis.ObjectiveIdentify and characterize a small molecule inhibitor of IgE-dependent mast cell activation for the treatment of allergic diseases.MethodsA cell-based high-throughput screen for small molecules that block IgE signaling was performed in cultured human mast cells. A potent inhibitor, referred to as R112, was selected and characterized by using biochemical and cell-based assays. R112 effects on IgE-dependent degranulation and cytokine production was measured in mast cells and basophils and compared with other mast cell inhibitors.ResultsR112 inhibited degranulation induced by anti-IgE cross-linking in mast cells (tryptase release, effective concentration for 50% inhibition [EC50] = 353 nmol/L) or basophils (histamine release, EC50 = 280 nmol/L), and by allergen (dust mite) in basophils (histamine release, EC50 = 490 nmol/L). R112 also blocked leukotriene C4 production and all proinflammatory cytokines tested. Subsequent molecular characterization indicated that R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor (inhibitory constant [Ki] = 96 nmol/L). Its onset of action was immediate, and the inhibition was reversible. Incubation of mast cells with R112 showed that cytokine production in mast cells was dependent on sustained activation of the FcɛRI-Lyn–spleen tyrosine kinase pathway. Unlike other mast cell inhibitors, R112 was able to completely inhibit all three IgE-induced mast cell functions: degranulation, lipid mediator production, and cytokine production.ConclusionR112 potently, completely, and rapidly abrogated all mast cell activation cascades triggered by IgE receptor cross-linking.Clinical implicationsR112 and its analogues offer a new modality in the treatment of allergic rhinitis. Activation of the IgE receptor, FcɛRI, in mast cells is the key mechanism initiating and propagating pathophysiological responses in allergic rhinitis. Identify and characterize a small molecule inhibitor of IgE-dependent mast cell activation for the treatment of allergic diseases. A cell-based high-throughput screen for small molecules that block IgE signaling was performed in cultured human mast cells. A potent inhibitor, referred to as R112, was selected and characterized by using biochemical and cell-based assays. R112 effects on IgE-dependent degranulation and cytokine production was measured in mast cells and basophils and compared with other mast cell inhibitors. R112 inhibited degranulation induced by anti-IgE cross-linking in mast cells (tryptase release, effective concentration for 50% inhibition [EC50] = 353 nmol/L) or basophils (histamine release, EC50 = 280 nmol/L), and by allergen (dust mite) in basophils (histamine release, EC50 = 490 nmol/L). R112 also blocked leukotriene C4 production and all proinflammatory cytokines tested. Subsequent molecular characterization indicated that R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor (inhibitory constant [Ki] = 96 nmol/L). Its onset of action was immediate, and the inhibition was reversible. Incubation of mast cells with R112 showed that cytokine production in mast cells was dependent on sustained activation of the FcɛRI-Lyn–spleen tyrosine kinase pathway. Unlike other mast cell inhibitors, R112 was able to completely inhibit all three IgE-induced mast cell functions: degranulation, lipid mediator production, and cytokine production. R112 potently, completely, and rapidly abrogated all mast cell activation cascades triggered by IgE receptor cross-linking." @default.
• W2029388289 created "2016-06-24" @default.
• W2029388289 creator A5023123797 @default.
• W2029388289 creator A5025998233 @default.
• W2029388289 creator A5032350627 @default.
• W2029388289 creator A5032791546 @default.
• W2029388289 creator A5043924520 @default.
• W2029388289 creator A5055593298 @default.
• W2029388289 creator A5066099564 @default.
• W2029388289 creator A5068203353 @default.
• W2029388289 creator A5076863478 @default.
• W2029388289 creator A5087465996 @default.
• W2029388289 creator A5088767834 @default.
• W2029388289 date "2006-09-01" @default.
• W2029388289 modified "2023-09-25" @default.
• W2029388289 title "Identification of the Syk kinase inhibitor R112 by a human mast cell screen" @default.
• W2029388289 cites W1903287340 @default.
• W2029388289 cites W1980042341 @default.
• W2029388289 cites W1986542865 @default.
• W2029388289 cites W1988510980 @default.
• W2029388289 cites W2002967758 @default.
• W2029388289 cites W2008931469 @default.
• W2029388289 cites W2041726757 @default.
• W2029388289 cites W2046531335 @default.
• W2029388289 cites W2050601356 @default.
• W2029388289 cites W2054321852 @default.
• W2029388289 cites W2069808501 @default.
• W2029388289 cites W2073444018 @default.
• W2029388289 cites W2074653094 @default.
• W2029388289 cites W2087424636 @default.
• W2029388289 cites W2090895449 @default.
• W2029388289 cites W2099519675 @default.
• W2029388289 cites W2100279098 @default.
• W2029388289 cites W2108139380 @default.
• W2029388289 cites W2132795628 @default.
• W2029388289 cites W2138370786 @default.
• W2029388289 cites W2139494439 @default.
• W2029388289 cites W2143466612 @default.
• W2029388289 cites W2163617437 @default.
• W2029388289 cites W2171533033 @default.
• W2029388289 doi "https://doi.org/10.1016/j.jaci.2006.05.023" @default.
• W2029388289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16950297" @default.
• W2029388289 hasPublicationYear "2006" @default.
• W2029388289 type Work @default.
• W2029388289 sameAs 2029388289 @default.
• W2029388289 citedByCount "73" @default.
• W2029388289 countsByYear W20293882892012 @default.
• W2029388289 countsByYear W20293882892013 @default.
• W2029388289 countsByYear W20293882892014 @default.
• W2029388289 countsByYear W20293882892015 @default.
• W2029388289 countsByYear W20293882892016 @default.
• W2029388289 countsByYear W20293882892017 @default.
• W2029388289 countsByYear W20293882892018 @default.
• W2029388289 countsByYear W20293882892019 @default.
• W2029388289 countsByYear W20293882892020 @default.
• W2029388289 countsByYear W20293882892021 @default.
• W2029388289 countsByYear W20293882892022 @default.
• W2029388289 countsByYear W20293882892023 @default.
• W2029388289 crossrefType "journal-article" @default.
• W2029388289 hasAuthorship W2029388289A5023123797 @default.
• W2029388289 hasAuthorship W2029388289A5025998233 @default.
• W2029388289 hasAuthorship W2029388289A5032350627 @default.
• W2029388289 hasAuthorship W2029388289A5032791546 @default.
• W2029388289 hasAuthorship W2029388289A5043924520 @default.
• W2029388289 hasAuthorship W2029388289A5055593298 @default.
• W2029388289 hasAuthorship W2029388289A5066099564 @default.
• W2029388289 hasAuthorship W2029388289A5068203353 @default.
• W2029388289 hasAuthorship W2029388289A5076863478 @default.
• W2029388289 hasAuthorship W2029388289A5087465996 @default.
• W2029388289 hasAuthorship W2029388289A5088767834 @default.
• W2029388289 hasBestOaLocation W20293882891 @default.
• W2029388289 hasConcept C1122143 @default.
• W2029388289 hasConcept C141105273 @default.
• W2029388289 hasConcept C159654299 @default.
• W2029388289 hasConcept C164027704 @default.
• W2029388289 hasConcept C170493617 @default.
• W2029388289 hasConcept C175818844 @default.
• W2029388289 hasConcept C185592680 @default.
• W2029388289 hasConcept C203014093 @default.
• W2029388289 hasConcept C2776914184 @default.
• W2029388289 hasConcept C2777456892 @default.
• W2029388289 hasConcept C2778690821 @default.
• W2029388289 hasConcept C2779726688 @default.
• W2029388289 hasConcept C2781406822 @default.
• W2029388289 hasConcept C35174551 @default.
• W2029388289 hasConcept C42362537 @default.
• W2029388289 hasConcept C49802076 @default.
• W2029388289 hasConcept C55493867 @default.
• W2029388289 hasConcept C86803240 @default.
• W2029388289 hasConcept C98274493 @default.
• W2029388289 hasConceptScore W2029388289C1122143 @default.
• W2029388289 hasConceptScore W2029388289C141105273 @default.
• W2029388289 hasConceptScore W2029388289C159654299 @default.
• W2029388289 hasConceptScore W2029388289C164027704 @default.
• W2029388289 hasConceptScore W2029388289C170493617 @default.
• W2029388289 hasConceptScore W2029388289C175818844 @default.
• W2029388289 hasConceptScore W2029388289C185592680 @default.
• W2029388289 hasConceptScore W2029388289C203014093 @default.

• next